Studi Penambatan Molekuler Senyawa Tectoquinone Terhadap Enzim α-Glukosidase
Jurnal Fitofarmaka Indonesia · 2023
DOI: 10.33096/jffi.v10i2.1059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Jurnal Fitofarmaka Indonesia, 2023. Verfasst von Ahmad Najib und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
The investigation focused on conducting an in silico screening of chemical compounds isolated from Syzygium oblanceolatum (C.B.Rob) to identify potential bioactive compounds that could act as inhibitors of α-Glucosidase. This screening involved tectoquinone as the potential inhibitor for α-Glucosidase and employed the Autodock Vina Docking process. The target enzyme, α-Glucosidase, was used as the receptor with 20 binding sites on the enzyme receptor 1LWJ and the Autodock Vina program was utilized for this purpose. The values of ∆Gbind and the lowest RMSD were determined for each of the 20 targeted binding sites on 1LWJ, representing the free energy change (∆G) resulting from the docking. The docking results demonstrated that the free energy change (∆G) for the 20 targeted binding sites ranged from -6.346 kcal/mol to -9.720 kcal/mol. The most favorable free energy change (∆G) was observed at the 16th binding site with a value of -9.720 kcal/mol, while the highest was recorded at the 18th binding site with a value of -6.346 kcal/mol.
Zitieren
APA
Najib, A., Razak, R., & Mujtahid, I. F. (2023). Studi Penambatan Molekuler Senyawa Tectoquinone Terhadap Enzim α-Glukosidase. Jurnal Fitofarmaka Indonesia. https://doi.org/10.33096/jffi.v10i2.1059
Vancouver
Najib A, Razak R, Mujtahid IF. Studi Penambatan Molekuler Senyawa Tectoquinone Terhadap Enzim α-Glukosidase. Jurnal Fitofarmaka Indonesia. 2023. doi:10.33096/jffi.v10i2.1059
BibTeX
@article{Najib2023,
author = {Najib, Ahmad and Razak, Rais and Mujtahid, Izzatul Fikril},
title = {Studi Penambatan Molekuler Senyawa Tectoquinone Terhadap Enzim α-Glukosidase},
journal = {Jurnal Fitofarmaka Indonesia},
year = {2023},
doi = {10.33096/jffi.v10i2.1059}
}
EUVIMED